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The vast increase of chronic kidney disease (CKD) has attracted considerable attention worldwide, and the development of a
novel therapeutic option against a representative kidney disease that leads to CKD, mesangial proliferative glomerulonephritis
(MsPGN) would be signiﬁcant. Peroxisome proliferator-activated receptor α (PPARα), a member of the steroid/nuclear receptor
superfamily, is known to perform various physiological functions. Recently, we reported that PPARα in activated mesangial cells
exerted anti-inﬂammatory eﬀects and that the deﬁciency of PPARα resulted in high susceptibility to glomerulonephritis. To
investigate whether PPARα activation improves the disease activity of MsPGN, we examined the protective eﬀects of a PPARα
agonist, cloﬁbrate, in a well-established model of human MsPGN, anti-Thy1 nephritis, for the ﬁrst time. This study demonstrated
that pretreatment with cloﬁbrate (via a 0.02% or 0.1% cloﬁbrate-containing diet) continuously activated the glomerular PPARα,
which outweighed the PPARα deterioration associated with the nephritic process. The PPARα activation appeared to suppress the
NF-κB signaling pathway in glomeruli by the induction of IκBα, resulting in the reduction of proteinuria and the amelioration
of the active inﬂammatory pathologic glomerular changes. These ﬁndings suggest the antinephritic potential of PPARα-related
medicines against MsPGN. PPARα-related medicines might be useful as a treatment option for CKD.
1.Introduction
The vast increase in chronic kidney disease (CKD) has
attractedconsiderableattentionworldwide,sinceCKDisone
of the most important risk factors for cardiovascular events,
the induction of kidney replacement therapies, and death
[1].Amongmanytypesofprimarykidneydisease,mesangial
proliferative glomerulonephritis (MsPGN) including IgA
nephropathy is a representative proteinuric kidney disease
that leads to CKD [2, 3]. Various medications such as
angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, ﬁsh oil, statins, hydroxymethylglutaryl-
CoA reductase inhibitors, immunosuppressive therapy, anti-
platelets, and anticoagulants have been proposed; however, it
remains diﬃcult to control the nephritic activity associated
with severe inﬂammatory pathologic glomerular changes
[4]. It is known that the marked activation of nuclear
f a c t o rk a p p aB( N F - κB) was detected in various kidney cells
from MsPGN patients, including mesangial cells, glomerular
endothelial and epithelial cells, tubular epithelial cells, and
inﬁltrating cells and that the NF-κB transcriptional activa-
tion is signiﬁcantly involved in the progression of kidney
tissue injury [5]. Therefore, the development of a novel ther-
apeutic option against NF-κBa c t i v a t i o ni na c t i v eM s P G N
would be signiﬁcant.
Peroxisome proliferator-activated receptor α (PPARα),
a member of the steroid/nuclear receptor superfamily of
ligand-dependent transcription factors, is known to perform
various physiological functions, including the maintenance
of lipid and glucose homeostasis, the regulation of cell2 PPAR Research
proliferation, and anti-inﬂammatory eﬀects via suppression
of the NF-κBp a t h w a y[ 6–13]. Recently, we reported that the
activated mesangial cells expressed a signiﬁcant amount of
PPARα and that the representative PPARα agonists, ﬁbrates,
exert anti-inﬂammatory eﬀects in an in vitro study using
murine mesangial cells stimulated by lipopolysaccharide
[14]. Moreover, we also showed that a deﬁciency of PPARα
resulted in high susceptibility to glomerulonephritis in an in
vivomurine study [15]. These ﬁndings suggestthat glomeru-
lar PPARα activation might contribute to the treatment of
MsPGN.
Toobtainbasicevidenceconcerningthebeneﬁcialpoten-
tial of PPARα ligand against MsPGN, we examined the
glomerular protective eﬀects of a PPARα agonist, cloﬁbrate,
in a well-established rat model of human MsPGN, anti-
Thy1 nephritis. Anti-Thy1 nephritis, induced by anti-Thy1
antibody binding to the corresponding antigen on the mem-
brane of mesangial cells, is marked by obvious transient
inﬂammatory glomerular lesions, such as mesangial cell
proliferation, mesangiolysis, glomerular capillary aneurysm
formation, and extracapillary proliferation [16]. Several
earlier studies demonstrated that upregulation of the NF-κB
gene was greatly involved in the developmental process of
anti-Thy1 nephritis [17, 18]. The current study reveals for
the ﬁrst time that PPARα activation via cloﬁbrate treatment
wouldattenuatethe disease activity of anti-Thy1 nephritis by
suppressing glomerular NF-κB signaling.
2.MaterialsandMethods
2.1. Animals and Experimental Design. Male Wistar rats were
used in this study (age, 8 weeks; purchased from Nihon SLC,
Hamamatsu,Japan).Allratsweremaintainedinafacilityfree
of speciﬁc pathogens, housed in a temperature- and light-
controlled environment (25◦C; 12-h light/dark cycle), and
given tap water ad libitum.A l lp r o c e d u r e sw e r ep e r f o r m e d
in accordance with the guidelines of the Shinshu University,
the National Institutes of Health, and the Association for
Assessment and Accreditation of Laboratory Animal Care.
The rats were divided into three groups: a regular diet group
(Fib(−); n = 24), a low-dose cloﬁbrate-containing-diet
group (0.02% Fib; n = 12), and a high-dose cloﬁbrate-
containing-diet group (0.1% Fib; n = 24). The rats in
the Fib(−) group were fed a regular diet throughout the
experimental period. The cloﬁbrate-treated rats were fed a
0.02 or 0.1% cloﬁbrate-containing diet (drug weight/food
weight) beginning 5 days before the injection of anti-
Thy1 antibody, respectively. We measured the animals’ body
weight and daily food consumption every day. The mean
body weight and food consumption values in each group did
notchangesigniﬁcantlythroughouttheexperimentalperiod,
and did not diﬀer among groups (Table 1). Using these data,
the mean ± SD cloﬁbrate dosage was calculated (Table 1).
Cloﬁbrate was obtained from Wako (Tokyo, Japan). Anti-
Thy1 MsPGN was induced by a single intravenous injection
of a mouse anti-Thy1 monoclonal antibody-containing
solution. Concentrated anti-Thy1 antibody solution was
obtained from Cedarlane Laboratories (Ontario, Canada,
catalog no. CL005A). One vial of the commercial antibody
solution was diluted with 300μL of sterile saline, and it
was injected into each rat at a dose of 25μL/100g body
weight. No rat in any group died except those sacriﬁced
according to the study protocol throughout the experimental
period.Someratsweresacriﬁcedforanalysisaccordingtothe
protocolatdays0,4,7,and14.Thenumbersofratssubjected
to analyses at days 0, 4, 7, and 14 were as follows: Fib(−)
group, n = 6; 0.02% group, n = 3; 0.1% group, n = 6, at
each day, respectively. The possibility of the induction failure
of nephritis was checked by means of the measurement of
urineproteinexcretionintheearlyphase,asdescribedbelow.
In the current study, all rats, which were injected to anti-
Thy1 antibody solution, developed signiﬁcant increases of
proteinuria at day 2, indicating perfect induction of anti-
Thy1 nephritis.
2.2. Pathological Analyses. Tissues from the kidneys of rats
i ne a c hg r o u pw e r eﬁ x e di n4 %p a r a f o r m a l d e h y d e .D e p a r a f -
ﬁnized sections were stained with hematoxylin & eosin,
periodic acid Schiﬀ, or periodic acid-methenamine-silver.
Since anti-Thy1 nephritis markedly caused various acute
inﬂammatory glomerular changes including mesangial cell
proliferation, mesangiolysis, glomerular capillary aneurysm
formation, and extracapillary proliferation, we evaluated
these inﬂammatory glomerular changes using semiquanti-
tative pathologic analyses. For the analyses, 50 randomly
selected glomeruli from each kidney section were studied.
The degree of mesangial cell proliferation was estimated
using a scale that ranged from 0 to 3 (0, normal; 1, mild; 2,
moderate; 3, severe). Indices were calculated using the
following formula: Index = (n0 × 0) + (n1 × 1) + (n2 × 2) +
(n3 × 3)/50 (

n = 50). The levels of severity of the me-
sangiolysis, glomerular capillary aneurysm formation, and
crescent formation were assessed by the appearance rate of
eachﬁnding(%ofthedamagedglomeruli).Thesepathologic
analyses were performed in a blinded manner by two
observers who were unaware of the study protocol.
2.3. Intranuclear Transcription Factor Assay. The speciﬁc
transcriptionfactorDNA-bindingactivitiesofPPARαorNF-
κB in nuclear extracts were analyzed using enzyme-linked
immunosorbent assay (ELISA) kits (Cayman Chemical, CA,
USA). The speciﬁc double-stranded DNA sequence contain-
ing the PPAR or NF-κB response element was immobilized
onto the bottoms of the wells of a 96-well plate. PPARα
or NF-κB, contained in a nuclear extract, bound to each
speciﬁc response element and was detected by the addition
of a speciﬁc primary antibody. After secondary antibody
binding, the DNA-binding activity was visualized calori-
metrically. These ELISA assays are nonradioactive, sensitive
established methods, and recently replaced the radioactive
electrophoretic mobility shift assay. Nuclear protein was
extracted from isolated glomeruli using the NE-PER Nuclear
and Cytoplasmic Extraction Kit (Thermo Scientiﬁc, MA,
USA). Glomeruli were isolated from the kidney cortex of
each rat by mechanical sieving techniques as described
previously [19]. The nuclear protein samples, as well asPPAR Research 3
Table 1: Systemic change and estimated dose of cloﬁbrate in anti-Thy1 nephritis rats.
Parameter Fibrate (−) group 0.02% ﬁbrate group 0.1% ﬁbrate group
Day 0 Day 4 Day 7 Day 14 Day 0 Day 4 Day 7 Day 14 Day 0 Day 4 Day 7 Day 14
BW (g) 248 ± 26 254 ± 33 256 ± 38 267 ± 54 257±16 259 ± 48 264 ± 35 265 ± 47 254 ± 21 258 ± 39 263 ± 30 267 ± 40
sBP (mmHg) 152 ± 17 158 ± 20 158 ± 15 150±10 155 ± 10 149 ± 12 152 ± 18 153 ± 6 151 ± 16 157 ± 15 155 ± 20 158 ± 15
HR (beat/min) 400 ± 16 407 ± 30 410 ± 20 400 ± 20 393 ± 11 400 ± 10 406 ± 21 404±25 396 ± 26 405 ± 36 403 ± 30 402±15
FC (g/day) 20.1 ± 51 9 ± 3 18.5 ± 5 18.3 ± 5 18.2 ± 2 18.7 ± 2 19.6 ± 2 18.6 ± 5 18.9 ± 3 18.7 ± 1 19.5 ± 31 9 ± 6
Clo dose (mg/kg) 0 0 0 0 14.2 14.1 14.8 14.1 74.5 72.4 74.1 71.2
BW, body weight; sBP, systolic bood pressure; HR, heart rate; FC, food consumption; Clo, cloﬁbrate.
These parameters were not aﬀected by the induction of anti-Thy1 nephritis. There was no signiﬁcant diﬀerence among groups.
Table 2: Primer sequences for quantitative real-time PCR assay.
Gene name Primers GenBank access no.
PPARα Forward: 5 -GACAAGGCTCAGGATACCACTATG-3 
Reverse: 5 -TTGCAGCTTCGATCACACTTGTC-3  NM 013196
ACOX Forward: 5 -GGGCCTGACAGAAGCCTACAAG-3 
Reverse: 5 -AAGGTCGACAGAGGTTAGGTTCCA-3  NM 017340
IκBα Forward: 5 -TGACCATGGAAGTGATTGGTCAG-3 
Reverse: 5 -GATCACAGCCAAGTGGAGTGGA-3  NM 001105720
COX2 Forward: 5 -GCGACTGTTCCAAACCAGCA-3 
Reverse: 5 -TGGGTCGAACTTGAGTTTGAAGTG-3  NM 017232
ICAM1 Forward: 5 -ACAAGTGCCGTGCCTTTAGCTC-3 
Reverse: 5 -GATCACGAAGCCCGCAATG-3  NM 012967
TNFα Forward: 5 -AACTCGAGTGACAAGCCCGTAG-3 
Reverse: 5 -GTACCACCAGTTGGTTGTCTTTGA-3  NM 012675
PPARα, peroxisome proliferator-activated receptor α; ACOX, acyl-CoA oxidase; IκBα, inhibitory factor κBα; COX2, cyclooxygenase-2; ICAM1, intercellular
adhesion molecule-1; TNFα, tumor necrosis factor-α.
commercial positive control protein reagents and blank
samples, were subjected to ELISA in triplicate. The mean
optical density (OD) of the blank sample was subtracted
from the OD of each sample, and the value was normalized
to each nuclear protein amount and subsequently expressed
as the change relative to the value of the control rats (Fib(−)
group at day 0).
2.4. Analyses of mRNA. Analyses of mRNA were performed
using quantitative real-time PCR as described previously
[20–22]. One microgram of total RNA, extracted from
isolated glomeruli obtained from each rat, was reverse-
transcribed using oligo(dT) primers and Superscript reverse
transcriptase (Invitrogen, CA). The cDNAs were quanti-
ﬁed with an ABI PRISM 7700 sequence detection system
(Applied Biosystems, CA) using speciﬁc primers and SYBR
Green double-stranded DNA binding dye I. The speciﬁc
primers were designed as shown in Table 2.F o rr e l a t i v e
quantiﬁcation of mRNA, glyceraldehyde-3-phosphate dehy-
drogenase was used as an internal control, and the relative
expression of RNA was calculated by the comparative
threshold cycle (Ct) method. The expression was expressed
intermsofthechangerelativetotheexpressionofthecontrol
[Fib(−) group of rats at day 0]. PCR reactions were carried
out in triplicate and averaged for analysis.
2.5. Miscellaneous Methods. Throughout the experimental
period,urinecollectionswerecarriedoutdaily.Urineprotein
concentrations were measured as described previously [7].
Serum urea nitrogen and serum creatinine were measured by
enzymatic methods using a clinical analyzer (JCA-BM2250;
JEOL, Tokyo, Japan).
2.6. Statistical Analysis. Analysis of signiﬁcant diﬀerences
with respect to the interactive eﬀects of the two factors
(ﬁbrate treatment and anti-Thy1 antibody injection) was
performed using one-way ANOVA. Throughout the paper,
signiﬁcant diﬀerences from the respective day 0 group are
indicated with number signs (#P<0.05, ##P<0.01, ###P<
0.001), while signiﬁcant diﬀerences between regular-diet and
cloﬁbrate-dietgroupsareindicatedwithasterisks(∗P<0.05,
∗∗P<0.01, ∗∗∗P<0.001).
3. Results
3.1.TheAntiproteinuricEﬀectbyCloﬁbrateTreatmentinAnti-
Thy1 Nephritis. Pretreatment with cloﬁbrate for 5 days and
the inductive procedure of anti-Thy1 nephritis did not cause
any systemic changes to body weight, food consumption,
urine volume, blood pressure, or heart rate (Table 1).
Pretreatment with cloﬁbrate did not aﬀect the urinalysis in
any group of rats; however, the anti-Thy1 antibody injection
immediately and dramatically increased daily urine protein
e x c r e t i o ni na l lg r o u p s( Figure 1). Especially in the Fib(−)
group, massive proteinuria appeared within 2 days and then
gradually decreased. The cloﬁbrate treatment attenuated the
marked elevation of proteinuria throughout the experimen-
tal period in a dose-dependent manner. Serum levels of urea4 PPAR Research
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Figure 1: Alteration of kidney function by cloﬁbrate pretreatment in anti-Thy1 nephritis rat. (a) Time course of the daily urinary protein
excretion in anti-Thy1 nephritis rats. ((b) and (c)) Serum concentrations of urea nitrogen and creatinine, respectively. The cloﬁbrate-
pretreatment group was fed a 0.02% or 0.1% cloﬁbrate-containing diet from 5 days before anti-Thy1 antibody injection. The start time
of the anti-Thy1 antibody injection was designated as day 0. Values represent means ± SD (n = 24, 12, and 24 for the Fib(−), 0.02% ﬁbrate,
and0.1%ﬁbrategroups,resp.).Signiﬁcantdiﬀerences fromtherespectiveday0groupsareindicatedwithnumbersigns (###P<0.001),while
signiﬁcant diﬀerences between regular-diet and cloﬁbrate-diet groups are indicated with asterisks (∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001).
nitrogen and creatinine were prone to increase in all groups;
however, there were no signiﬁcant diﬀerences among the
threegroups.Theseﬁndingssuggestanantiproteinuric eﬀect
of cloﬁbrate treatment against anti-Thy1 nephritis.
3.2. The Amelioration of Glomerular Active Lesions by Cloﬁ-
brate Treatment. To evaluate kidney damage, we carried out
pathological analyses. In the Fib(−) group, an acute ﬁnding
of mesangial damage, mesangiolysis, induced by anti-Thy1
antibody appeared within 4 days, followed by various
severe glomerular inﬂammatory changes, such as glomeru-
lar capillary aneurysm formation, crescent formation, and
mesangial cell proliferation (Figure 2). The semiquantitative
pathological analyses demonstrated that the levels of severity
oftheseacuteglomerularlesionsreachedpeaklevelsonday7PPAR Research 5
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Figure 2: Light microscopic analyses of kidney injuries. (a) Representative micrographs of the kidney in anti-Thy1 nephritis rats. Kidney
sections were stained with periodic acid methenamine silver (PAM). (b) Semiquantiﬁcation of pathologic changes including mesangial
cell proliferation, mesangiolysis, glomerular capillary aneurysm formation, and crescent formation. Values are means ± SD. Signiﬁcant
diﬀerences from the respective day 0 groups are indicated with number signs (##P<0.01, ###P<0.001), while signiﬁcant diﬀerences between
regular-diet and cloﬁbrate-diet groups are indicated with asterisks (∗∗∗P<0.001).6 PPAR Research
in the Fib(−) group. The ﬁndings of mesangiolysis, capillary
aneurysm, and crescent improved spontaneously on day 14,
while the high level of mesangial cell proliferation continued
in this group. The pretreatment with cloﬁbrate caused
no glomerular change at day 0. This treatment markedly
moderated the acute ﬁndings induced by anti-Thy1 antibody
in a dose-dependent manner throughout the experimental
period. These ﬁndings suggest that pretreatment with cloﬁ-
brate ameliorated the glomerular active lesions of anti-Thy1
nephritis.
3.3. The Activation of Glomerular PPARα by Cloﬁbrate
Treatment. To investigate the degree of PPARα activation via
cloﬁbrate treatment, we examined the binding activities of
intranuclear PPARα with PPAR response element (PPRE),
using nuclear protein samples from isolated glomeruli of
each group. In the Fib(−) group, the induction of anti-Thy1
nephritis obviously decreased the PPRE binding activity
of PPARα at days 7 and 14 in a time-dependent manner
(Figure 3). The pretreatment with cloﬁbrate increased the
glomerular PPARα activity at day 0 (before the anti-Thy1
antibody injection), in a dose-dependent manner. In spite of
theinductionofanti-Thy1nephritis,thehigh-dosecloﬁbrate
treatment further enhanced the increase of PPARα activity,
and the low-dose treatment maintained the activated level as
of day 7. Then, the PPARα activities ofboth cloﬁbrategroups
decreased at day 14, but the level of activity was still high as
compared to that of the control rats. These ﬁndings suggest
that the PPRE binding activity of PPARα deteriorated due to
the development of anti-Thy1 nephritis in the control group;
however, the pretreatment with cloﬁbrate outweighed this
deterioration and continuously activated glomerularPPARα.
To verify the enhancement of the transcriptional activity of
glomerular PPARα, we next examined the mRNA expression
levels of PPARα and of its representative target molecule,
acyl-CoA oxidase (ACOX). In the Fib(−) group, the induc-
tion of anti-Thy1 nephritis decreased the mRNA expressions
of PPARα and ACOX, a result that was identical to the results
of the PPRE binding assay and suggesting the deterioration
of glomerular PPARα (Figure 4). The pretreatment with
cloﬁbrate increased the mRNA expression of PPARα and
ACOX at day 0 in a dose-dependent manner. The induction
of anti-Thy1 nephritis decreased these expressions in each
group; however, the PPARα and ACOX expressions of both
cloﬁbrate treatment groups remained over the baseline level
of the control rats. These ﬁndings support the ﬁnding of
continuous activation of PPARα via the cloﬁbrate treatment.
This activation was resistant to the PPARα deterioration
associated with the nephritic process.
3.4.TheSuppressionoftheNF-κBPathwaybyCloﬁbrateTreat-
ment. Since many earlier studies have demonstrated that the
activated PPARα exerts anti-inﬂammatory eﬀects through
suppression of the NF-κBp a t h w a y[ 23, 24], we next exam-
inedthebindingactivitiesofnuclearNF-κB(p65)withaNF-
κBresponseelement.Theresponseelementbindingactivities
of NF-κB did not diﬀer among the groups at day 0. However,
anti-Thy1 antibody injection increased the NF-κB binding
activities in the Fib(−) and low-dose cloﬁbrate groups
(Figure 3). The peak phase of NF-κBa c t i v a t i o ni nb o t h
groups appeared to be around day 7. On the other hand, the
high-dose cloﬁbrate treatment dramatically suppressed the
NF-κB activation throughout the experimental period. The
time course of NF-κB activation appeared to be consistent
with that of the pathological activities of anti-Thy1 nephritis
in each group. It is known that activated PPARα suppresses
the NF-κB pathway via the induction of the inhibitory
factor κBα (IκBα)[ 23]. The mRNA analyses demonstrated
thatthehigh-dosecloﬁbratetreatmentcontinuouslyinduced
IκBα expression and decreased the high mRNA levels
of proinﬂammatory mediators including cyclooxygenase-2
(COX2), tumor necrosis factor-α (TNFα), and intercellular
adhesion molecule-I (ICAM1), which were NF-κBt a r g e t
molecules (Figure 4). These ﬁndings suggest that the anti-
Thy1 antibody injection induced the continuous activation
of the NF-κB signaling pathway in glomeruli followed by
an increase of proinﬂammatory mediators and that this
proinﬂammatory pathway was suppressed considerably by
the induction of IκBα, which might be mediated by PPARα
activation.
4. Discussion
The current study demonstrated that pretreatment with
cloﬁbrate exerted antiproteinuric eﬀects and ameliorated
the active glomerular pathologic inﬂammatory changes in
rat anti-Thy1 nephritis. The pretreatment with cloﬁbrate
continuously activated the glomerular PPARα, which out-
weighed the PPARα deterioration associated with the neph-
ritic process. This glomerular PPARα activation would
suppress the NF-κB signaling pathway via the induction
of IκBα and result in beneﬁcial antinephritic eﬀects. These
ﬁndings indicate the anti-nephritic potentiality of PPARα-
related medicines.
Several metabolic experimental studies, including
murine studies employing a high-fat-diet-induced glomer-
ularinjurymodeloradiabeticnephropathymodel,havealso
demonstrated the beneﬁcial properties of the PPARα agonist
ﬁbrates in reducing glomerular lesions [25–28]. These
studies suggested various beneﬁcial glomerular protective
eﬀectsofﬁbratesasfollows.First,PPARαactivationimproves
the lipid metabolic abnormality in glomeruli. Second,
PPARα activation attenuates the glomerular oxidative stress.
Third, PPARα activation ameliorates systemic insulin
resistance, lipid abnormality, energy homeostasis, hyper-
tension, and vascular injuries. These pathogenic abnormal-
ities are known to induce secondary activation of the NF-κB
signaling pathway and accumulation of the extracellular
matrix in glomeruli, resulting in glomerular failure [25].
Using these metabolic experimental models, it might be
diﬃcult to detect whether PPARα agonists have direct
anti-inﬂammatory eﬀects that protect glomeruli. In
contrast to these metabolic models, the mechanism of
glomerular injury of anti-Thy1 nephritis is due to the
direct inﬂammatory response by complement (C5b-9)-
induced activation of the NF-κB signaling pathway [16, 17].PPAR Research 7
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Figure 3: Alteration of intranuclear transcription factor activities. (a) The PPAR response element-binding activities of intranuclear PPARα
from glomeruli in each group of anti-Thy1 nephritis rats. (b) The NF-κB response element-binding activities of intranuclear NF-κBi ne a c h
group. For these assays, the nuclear protein samples were subjected to ELISA in triplicate. The optical density (OD) for each sample was
corrected by that of a blank sample and by protein amount in each sample. The data were expressed as changes relative to the value for the
control rats (Fib(−) group of rats at day 0). Values are means ± SD. Signiﬁcant diﬀerences from the respective day 0 groups are indicated
with number signs (#P<0.05, ##P<0.01, ###P<0.001), while signiﬁcant diﬀerences between regular-diet and cloﬁbrate-diet groups are
indicated with asterisks (∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001).
Therefore, this animal model appeared to be suitable to
demonstrate the direct anti-inﬂammatory eﬀects of PPARα
in glomerulonephritis. Another earlier experimental study
using a rat antiglomerular basement membrane crescentic
glomerulonephritis model also indicated the direct anti-
inﬂammatory eﬀects of PPARα, thus supporting our
results [29]. The NF-κB-suppressing eﬀects of glomerular
PPARα might be useful for the treatment of the various
types of glomerulonephritis, including MsPGN, immune
complex kidney disease, crescentic glomerulonephritis, and
lupus nephritis, as well as metabolic abnormality-based
glomerulonephropathy.
In the current study, the NF-κB-suppressing eﬀects of
cloﬁbrate might be obscure in the low-dose ﬁbrate treatment
group; however, the antiproteinuric eﬀect in this group was
rather obvious, suggesting the existence of another mech-
anism of the anti-proteinuric eﬀect of PPARα agonist. A
recent study reported that a PPARα agonist, fenoﬁbrate,
eﬀectively reduced proteinuria and attenuated the reduction
level of glomerular nephrin, an important molecule regulat-
ing glomerular permeability, following doxorubicin-induced
podocyte injuries [30]. This study also demonstrated that
PPARα-null mice exhibited susceptibility to doxorubicin-
induced proteinuria, which was associated with lower
expression of nephrin compared with wild-type mice. This
paper suggests the existence of an anti-proteinuric eﬀect
of PPARα agonist via the maintenance eﬀect of nephrin.
Several previous studies reported that the nephrin protein
expression in the glomeruli of anti-Thy1 nephritis was weak
and exhibited a discontinuous pattern as determined by
immunostaining [31]. Therefore, the anti-proteinuric eﬀects
of PPARα agonists might be derived from this protective
eﬀect of podocytes, as well as from NF-κB-suppressing
eﬀects.
It is known that PPARα is expressed more highly in
proximal tubular epithelial cells (PTECs) than in glomeruli,
and tubular PPARα exerts a protective eﬀect in PTECs via
the amelioration of fatty acid catabolism, the decreasing
of oxidative stress and apoptosis, and the suppression of
NF-κB singling [13, 32]. These tubular protective eﬀects of
PPARα were detected in various types of tubulointerstitial
injury models, such as protein-overload nephropathy (the
toxicity of excess fatty acids), unilateral ureteral obstruction,
5/6 nephrectomy, ischemia/reperfusion injury, and cisplatin8 PPAR Research
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Figure 4: Alteration of mRNA expression of target molecules of transcription factors. mRNAs were obtained from glomeruli of each group
of rats. The expression of mRNAs for the target molecules of PPARα (a) and NF-κB (b), including PPARα,A C O X ,I κBα,C O X 2 ,T N F α,a n d
ICAM1, was measured with real-time PCR. For relative quantiﬁcation of mRNA, glyceraldehyde-3-phosphate dehydrogenase was used as
an internal control, and the relative expression of RNA was calculated by the comparative threshold cycle (Ct) method. The expression was
expressed as the change relative to that of the control rats (Fib(−) group of rats at day 0). PCR reactions were carried out in triplicate and
averaged for analysis. Values represent means ± SD. Signiﬁcant diﬀerences from the respective day 0 groups are indicated with number signs
(#P<0.05, ##P<0.01, ###P<0.001), while signiﬁcant diﬀerences between regular-diet and cloﬁbrate-diet groups are indicated with asterisks
(∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001).
injury [13, 33–35]. In the current study, anti-Thy1 nephritis
induced a high level of proteinuria, a representative tubu-
lotoxic factor; however, the proteinuria was transient, so
tubulointerstitial changes were scarcely detected throughout
the experimental period. Therefore, we could not detect the
protective eﬀects of PPARα against tubulointerstitial injuries
derived from a high level of proteinuria in this model. In
order to detect such eﬀects, we would have to perform
another experiment using models exhibiting continuous
excretion of proteinuria in the future.
In the current study, we used cloﬁbrate to investigate the
antinephritic potential of PPARα-related medicines, since
this molecule was established as a representative beneﬁcial
medicine activating PPARα. However, we recommend the
careful use of ﬁbrates when clinical physicians treat kidney
disease patients because the renal toxicity by excess serum
accumulation of the ﬁbrates was often detected in the
animal models of kidney dysfunction [36]. The mechanism
of the renal toxicity of ﬁbrates was not fully understood;
however, our earlier studies reported that excess-dose cloﬁ-
brate treatment induced considerable oxidative stress due
to a PPARα-dependent mechanism, such as the induction
of PPARα-regulated ROS-generating enzymes (acyl-CoA
oxidase, cytochrome P450 4A, and NADPH oxidase) andPPAR Research 9
the enhancement of mitochondrial fatty acid β-oxidation
[13,37].Furthermore,ourrecentstudyreportedthatﬁbrates
could also enhance oxidative stress in a PPARα-independent
manner, as well as by a PPARα-dependent mechanism
[36]. The unfavorable oxidative eﬀect of ﬁbrates treatment
appeared to surpass the antioxidative eﬀects of PPARα
activation in the situation of excess drug accumulation in the
serum;thereforeadequatedosemanagementwouldbeessen-
tial for patients with kidney dysfunction. The earlier study
demonstrated that the marked elevation of oxidative stress,
induced by excess serum accumulation of ﬁbrates, exerted
proximal tubular epithelial cell toxicities such as tubular
dilatation, tubular atrophy, and tubular cast formation [36].
Interestingly, the glomerular toxicity of ﬁbrates was not
detected, suggesting that excess ﬁbrates exert only tubular
toxicity without glomerular toxicity [36]. In the current
study, the anti-Thy1 nephritic process resulted in transient
glomerular damage without tubular damage; therefore, this
limited situation might contribute to the good results
of ﬁbrate eﬀects, obvious glomerular protection, and less
tubular toxicity. On the other hand, in the human case of
many types of chronic progressing glomerulonephritis, a
considerable level of gradual secondary tubular damage gen-
erally appears; therefore, the tubular toxic eﬀects of ﬁbrates
might become obvious, especially after CKD has progressed.
With regard to the safe use of ﬁbrates, we must be clear
that the results of this study would not provide long-term
safety veriﬁcation for CKD patients. Furthermore, in order
to prevent excess drug accumulation and the associated
toxicities, we employed a pretreatment protocol established
via past animal study [36] in which an adequate dose of
ﬁbrate was started before the appearance of apparent kidney
dysfunction. In these speciﬁc situations, we succeeded in
detecting beneﬁcial anti-nephritic eﬀects of ﬁbrates without
adverse renal eﬀects in the current study. We believe that
the results are important when considering the beneﬁcial
potential of PPARα-related medicine in treating glomeru-
lonephritis. In humans, two clinical trials have reported that
ﬁbrates suppressed microalbuminuria in patients with early
diabetic nephropathy; however, kidney dysfunction was not
obviously improved [38, 39]. The results of these clinical
trials might be derived from the delicate balance between the
beneﬁcial eﬀects of PPARα activation and the renal toxicity
of ﬁbrates. In the future, the development of a novel PPARα
agonist exhibiting stable pharmacokinetics under kidney
dysfunction is needed.
5. Conclusions
Taken together, the current results suggest that pretreatment
with a representative PPARα agonist, cloﬁbrate, exerts a
protective function against anti-Thy1 nephritis via the
suppression of glomerular NF-κB signaling for the ﬁrst time.
The developmental process of anti-Thy1 nephritis decreased
glomerular PPARα expression and weakened its function,
while the pretreatment with an appropriate dose of cloﬁbrate
appeared to outweigh this deterioration. However, there are
severallimitations toour study. First, the use ofpretreatment
before nephritis might not ﬁt the actual clinical situation of
the treatment for human kidney disease. The investigation
of the beneﬁcial eﬀects of a treatment administered after the
initiation of anti-Thy1 nephritis using a novel medicine, a
high serum concentration of which is not caused by kidney
dysfunction or scarcely exerts toxicity, is needed in the
future. Second, there are known to be species diﬀerences
in PPARα activation via ﬁbrate treatment between rodents
and humans [40]. Therefore, we could not directly apply the
results of the current study to human patients. In order to
evaluate the anti-nephritic eﬀect of human PPARα function,
an investigation using PPARα-humanized mice might be
useful [41]. Third, anti-Thy1 nephritis is a very famous rat
model resembling human MsPGN; however this nephritis
could be produced only in rats. Therefore, we have to verify
the anti-nephritic eﬀects of PPARα agonists using various
nephritic models in the future. Nevertheless, the potential
anti-nephritic eﬀects of PPARα activation suggested in the
currentstudywillbe valuableforthedevelopment ofauseful
therapeutic strategy to treat glomerulonephritis.
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